Sarepta Therapeutics (SRPT) Financial Analysis & Valuation | Quarter Chart
Sarepta Therapeutics (SRPT)
SRPTPrice: $16.67
Fair Value: 🔒
🔒score
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dyst... more
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery a... more
Description
Shares
| Market Cap | $1.76B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Douglas S. Ingram |
| IPO Date | 1997-06-04 | CAGR | 0.4% |
| Employees | 1,372 | Website | www.sarepta.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SRPT chart loading...
Fundamentals
Technicals
| Enterprise Value | $2.86B | P/E Ratio | 47.63 |
| Forward P/E | 6.56 | PEG Ratio | — |
| P/S Ratio | 0.81 | P/B Ratio | 1.16 |
| P/CF Ratio | 9.99 | P/FCF Ratio | 16.43 |
| EPS | $0.35 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -2.2% | Gross Margin | 0.62% |
| Operating Margin | -0.02% | Profit Margin | 0.03% |
| ROE | 0.05% | ROA | 0.02% |
| ROCE | -0.02% | Current Ratio | 4.63 |
| Quick Ratio | 2.62 | Cash Ratio | 0.93 |
| Debt/Equity | 0.69 | Interest Coverage | -0.97 |
| Altman Z Score | 0.09 | Piotroski Score | 8 |